ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2005

Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis

qingyan li1, Jianguo Li1, Mengwen Niu1, Tianshu chu1 and lemei an2, 1Henan Provincial People's Hospital, zhengzhou, China (People's Republic), 2Henan Provincial People's Hospital, zhengzhou

Meeting: ACR Convergence 2025

Keywords: Heart disease, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1990–2014) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: While the relationship between serum uric acid (SUA) and coronary artery disease (CAD) remains controversial, emerging evidence suggests a particularly significant association in patients lacking traditional cardiovascular risk factors. The specific role of hyperuricemia in determining CAD severity in non-hypertensive, non-diabetic populations warrants further investigation.

Methods: In this retrospective cohort study, we analyzed 716 consecutive CAD patients undergoing percutaneous coronary intervention (PCI), with a focus on 279 individuals without hypertension or diabetes. We employed multivariable logistic regression and stratified analyses to assess the independent association between SUA levels and multiple stent implantation (≥2 stents), a robust indicator of CAD complexity and prognosis. Hyperuricemia was defined using gender-specific thresholds ( >420 μmol/L for males and postmenopausal females; >360 μmol/L for premenopausal females).

Results: In the overall cohort, multivessel disease (OR=2.27, 95% CI:1.94–3.96, p < 0.001) and diabetes (OR=1.47, 95% CI:1.05–2.07, p=0.027) independently predicted multiple stent placement. Notably, in the non-hypertensive, non-diabetic subgroup, hyperuricemia emerged as a strong independent predictor (OR=4.62, 95% CI:1.93–11.07, p=0.001), exceeding the predictive value of multivessel disease (OR=3.16, 95% CI:1.78–5.55, p < 0.001). No significant association was observed between SUA levels and stent number in the broader cohort.

Conclusion: Elevated serum uric acid independently predicts complex coronary lesions requiring multiple stent placements in non-hypertensive, non-diabetic CAD patients. These findings suggest that uric acid assessment may enhance risk stratification in this specific patient population, warranting further investigation into its clinical implications.


Disclosures: q. li: None; J. Li: None; M. Niu: None; T. chu: None; l. an: None.

To cite this abstract in AMA style:

li q, Li J, Niu M, chu T, an l. Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/elevated-serum-uric-acid-as-an-independent-risk-factor-for-multiple-stent-placement-in-non-hypertensive-non-diabetic-patients-with-coronary-artery-disease-a-retrospective-cohort-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-serum-uric-acid-as-an-independent-risk-factor-for-multiple-stent-placement-in-non-hypertensive-non-diabetic-patients-with-coronary-artery-disease-a-retrospective-cohort-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology